Menu Search
Equities

Fresenius Medical Care AG

FMS:NYQ

Fresenius Medical Care AG

Actions
Health CareHealth Care Providers
  • Price (USD)21.30
  • Today's Change-0.03 / -0.14%
  • Shares traded229.66k
  • 1 Year change+24.71%
  • Beta0.9172
Data delayed at least 15 minutes, as of Nov 09 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Fresenius Medical Care AG's net income fell -25.90% from 673.41m to 499.00m despite relatively flat revenues.
Gross margin25.14%
Net profit margin4.57%
Operating margin8.11%
Return on assets2.58%
Return on equity4.77%
Return on investment3.32%
More ▼

Cash flow in EURView more

In 2023, Fresenius Medical Care AG increased its cash reserves by 12.05%, or 153.44m. The company earned 2.63bn from its operations for a Cash Flow Margin of 13.51%. In addition the company used 544.23m on investing activities and also paid 1.86bn in financing cash flows.
Cash flow per share4.69
Price/Cash flow per share4.53
Book value per share24.88
Tangible book value per share-3.49
More ▼

Balance sheet in EURView more

Fresenius Medical Care AG has a Debt to Total Capital ratio of 43.10%, a lower figure than the previous year's 79.01%.
Current ratio1.37
Quick ratio1.02
Total debt/total equity0.8224
Total debt/total capital0.431
More ▼

Growth rates in EUR

Year on year, growth in earnings per share excluding extraordinary items dropped -25.94%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
Div yield(5 year avg)--
Div growth rate (5 year)--
Payout ratio (TTM)52.96%
EPS growth(5 years)-23.40
EPS (TTM) vs
TTM 1 year ago		46.46
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.